semaglutide brown fat Diet Plan for Optimal Weight Loss Results Exploring beyond numeric weight loss:

Description

2024 State Action Late last year, Illinois adopted a bill to cover certain weight loss and obesity medicines, including GLP-1s, under the state employee health plan

Monitoring considerations include: Regular assessment of gastrointestinal tolerability and hydration status Evaluation of any changes in MS symptoms, with low threshold for neurological consultation Glucose monitoring in diabetic patients, with adjustment of other antihyperglycemic agents as needed Periodic assessment of weight loss progress and nutritional adequacy Monitoring for signs of pancreatitis (severe abdominal pain) or gallbladder disease For Wegovy patients, monitoring for depression or suicidal thoughts Patient counseling should address realistic expectations regarding weight loss (typically 15% of body weight over 68 weeks with the 2.4 mg dose plus lifestyle intervention, with less at earlier timepoints), the chronic nature of therapy, and the importance of lifestyle modifications

The most common GLP-1 side effects are nausea, vomiting, constipation, and diarrhoea, and they usually settle after the first two to three months

Special Populations: Heart Failure In patients with both obesity and heart failure with preserved ejection fraction (HFpEF), semaglutide's cardiovascular benefits appear particularly robust

GLP-1 drugs, such as the blockbuster medication Ozempic (semaglutide) are now widely used in the treatment of obesity as well as T2D, offering reduced cardiovascular and renal morbidity to these patients